CERo Therapeutics Holdings, Inc. (CERO) Stock Analysis & Investment Frameworks
CERo Therapeutics Holdings, Inc. (CERO) stock analysis on Invetso. Review CERo Therapeutics Holdings, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
CERo Therapeutics Holdings, Inc. Company Overview
- Exchange: Other OTC
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
CERo Therapeutics Holdings, Inc. Key Financial Metrics
- Market Cap: $467816.00
- Revenue: $N/A
- ROE: 131.14%
- ROIC: 79.91%
- Dividend Yield: N/A
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
CERo Therapeutics Holdings, Inc. Investment Frameworks
Invetso analyzes CERo Therapeutics Holdings, Inc. (CERO) across the following frameworks:
- CERo Therapeutics Holdings, Inc. 10Y Growth Potential
- CERo Therapeutics Holdings, Inc. Scenario Analysis
- CERo Therapeutics Holdings, Inc. Risks & Opportunities
- CERo Therapeutics Holdings, Inc. Economic Moat
- CERo Therapeutics Holdings, Inc. Business Model
- CERo Therapeutics Holdings, Inc. Management
- CERo Therapeutics Holdings, Inc. SWOT Analysis
- CERo Therapeutics Holdings, Inc. Porter's 5 Forces
- CERo Therapeutics Holdings, Inc. PESTLE Analysis
- CERo Therapeutics Holdings, Inc. ESG Analysis
